
JJP Biologics sp. z o.o.
Research and experimental development in natural sciences and engineering
Overview
JJP Biologics is a Polish biotechnology company developing biological therapeutics supported by established companion diagnostics and a personalized-medicine strategy. Its pipeline includes JJP-1212, a potential CD89 antagonist for autoinflammatory diseases, and JJP-1008, a potential HVEM checkpoint inhibitor for solid tumors; the company seeks academic collaborators, investors, and biotechnology partners.
Financials
Revenue history (in k)
From the notes
| Current income tax (CIT due) | $0 | |
| Grants | $3,065,430 |
Filing timeliness
2 of 6 financial statements were filed late (the longest delay 198 days for 2020).
- 202503/07/2026
- 202402/06/2025
- 202327/02/2024
- 202228/06/2023
- 202102/09/2022
- 202001/06/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
Industry
Offer
- Biological testing
- Biologics development
- Biologic medicines
- Preclinical testing
- Clinical trials
Websites
The site is available in: Polish and English. The site targets these markets: United Kingdom.
- jjpbiologics.comHome – JJP BiologicsWordPress 7.1ElementorYoast SEONginx
Job offers
The company has its own careers page: jjpbiologics.com/jobs.
Authorized Representatives
Manner of representation
The making of declarations on behalf of the company requires the joint action of two members of the management board, or of one member of the management board jointly with a commercial proxy.
Supervisory board
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
| 57,580 | $777,687.74 | 89.9997% | |
Jerzy Andrzej Starak age 79 | 6,398 | $86,169.64 | 9.9722% |
Others | 18 | $243.11 | 0.0281% |
Beneficial owners
| Person | Rights |
|---|---|
Subsidiaries
Bank accounts
Registered as a VAT taxpayer on 2016-05-25.
15 1140 1010 0000 5562 9900 1003
41 1020 1026 0000 1102 0663 4168
63 1020 1026 0000 1902 0700 3629
Debt
No entries in the National Debtors Register (KRZ).
Real estate
| Type | Amount |
|---|---|
Buildings and premises | PLN 50,375PLN 50,375 |
MSiG notices
| Publication date | Event | |
|---|---|---|
| Feb 5, 2024 | Call to creditors | |
| Nov 18, 2020 | Call to creditors |
Public aid
13 public aid cases recorded, with a total value of $22,776,051.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jun 30, 2026 | Aid for research and development projects: experimental development | $4.4M$4,395,379 | Dyrektor Narodowego Centrum Badań i Rozwoju | |
| Jun 30, 2026 | Aid for research and development projects: industrial research | $4.2M$4,247,344 | Dyrektor Narodowego Centrum Badań i Rozwoju | |
| Apr 1, 2026 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $18,834$18,834 | Pomorska Specjalna Strefa Ekonomiczna sp. z o.o. |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2025-04-01 | Development of an innovative molecule for the immunotherapy of lung adenocarcinoma that induces targeted lysosomal degradation | $8.4M$8,357,172 | European Funds for a Modern Economy |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| KCR S.A. | $43,596,034.97 | kcrcro.com | ||
| Lipid Systems sp. z o.o. | $4,497,777.98 | lipidsystems.pl | ||
| Aronpharma sp. z o.o. | $3,197,864.33 | aronpharma.pl | ||
| Captor Therapeutics S.A. | $2,286,539.43 | captortherapeutics.pl | ||
| Molecure S.A. | $1,889,300.60 | molecure.com | ||
| Scope Fluidics S.A. | $1,264,188.85 | scopefluidics.com | ||
| Pikralida sp. z o.o. | $1,151,165.63 | pikralida.eu | ||
| Śląski Park Technologii Medycznych Kardio-Med Silesia sp. z o.o. | $969,037.30 | kmptm.pl | ||
| Nanogroup S.A. | $843,099.47 | nanogroup.eu | ||
| Bioresearch Group sp. z o.o. | $776,186.19 | bioresearch.pl |
Change history
| Date | Event | |
|---|---|---|
| 2025-12-05 | Share capital increase (2,879,000.00 PLN → 3,198,900.00 PLN) | |
| 2025-05-19 | Switch to PKD 2025 (7 PKD 2007 codes → 7 PKD 2025 codes) | |
| 2024-07-03 | Share capital reduction (58,980,000.00 PLN → 2,879,000.00 PLN) | |
| 2022-12-01 | Address change (Ul. Bobrowiecka 8, 00-728, Warszawa → Ul. Bobrowiecka 6, 00-728, Warszawa) | |
| 2022-05-01 | Share capital increase (2,505,000.00 PLN → 58,980,000.00 PLN) |
FAQ
Last updated: 2026-07-20
